logo

Antinuclear Antibody Test Market Size (2024 - 2029)

The antinuclear antibody test market is projected to experience significant growth, driven by factors such as the increasing prevalence of autoimmune diseases and the rising demand for diagnostic assays. The market's expansion is supported by government initiatives, favorable insurance policies, and new product launches. Despite the challenges posed by concerns over test reliability and limited awareness in developing regions, the market is expected to maintain stable growth. The ongoing research and development activities further contribute to the market's positive outlook, as they validate the efficacy of diagnostic assays and enhance their adoption.

Home Market Analysis Healthcare Research Medical Devices Research Medical Supplies Research Medical Consumables Research Laboratory Supplies Research Testing Kits Research Antinuclear Antibody Test Market Market Size

Market Size of Antinuclear Antibody Test Industry

Antinuclear Antibody Test Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 12.50 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Antinuclear Antibody Test Market Major Players

*Disclaimer: Major Players sorted in no particular order

Antinuclear Antibody Test Market Analysis

The antinuclear antibody test (ANA) market studied was anticipated to grow with a CAGR of 12.5% over the forecast period.

COVID-19 had a significant impact on the growth of the market during the forecast period. The study was conducted where a team of researchers screened several systemic autoantibodies to assess their association with the severity of COVID-19. The results were published in the article of medRxiv in January 2022, which stated that antinuclear antibodies (ANA) would be prevalent in COVID-19 patients up to one year after recovering from the SARS-CoV-2 infection. As a result, there is a good chance that the need for autoantibody diagnosis in COVID-19-infected patients will rise. This diagnosis may be done using an antinuclear antibody test. However, the number of COVID-19 cases has been subsidized but the risk of spread of infection due to new variants still persists and as the antinuclear antibody test is used in such diagnosis , the market is anticipated to have stable growth over the next 2-3 years.

Factors such as rising government initiatives with growing incidences of autoimmune diseases and favorable medical insurance and reimbursement policies are expected to drive market growth. Additionally, rising product launches will also boost the market. The increasing prevalence of autoimmune disorders, such as Sjogren's syndrome, acute motor axonal neuropathy, and others, increased the adoption of ANA testing. As per NCBI updated in July 2022, Guillain-Barre syndrome (GBS), which has an incidence of 0.4 to 2 per 100,000, has a significant impact on the healthcare system. Therefore, the increasing burden associated with GBS drives the demand for its effective diagnostic assay, thereby driving the antinuclear antibody test market over the study period.

Moreover, rising research and development activities proving the efficacies of diagnostic assays will further increase their adoption and is expected to have significant growth in the market. For instance, according to a study published in March 2022 in the journal Hematology, Transfusion and Cell Therapy, every patient must have a baseline level of the fluorescent antinuclear antibody (FANA) when they are diagnosed with autoimmune hemolytic anemia (AIHA). The presence of FANA gives a prognostic value and helps in deciding the treatment options which is expected to have a positive impact on the market.

Thus, the above-mentioned factors like the increasing burden of autoimmune diseases and new developments in the market are likely to increase the demand for the ANA test and the studied market is expected to grow significantly during the study period. However, increasing concerns about the reliability of antinuclear antibody tests and lack of awareness of the disease and effective treatment in developing economies are expected to hinder the market growth.

Antinuclear Antibody Test Industry Segmentation

As per the scope of the report, antinuclear antibodies (ANA) are a group of autoantibodies that bind to the contents of the cell nucleus. These are produced by an individual's immune system when it fails to adequately differentiate one's own and foreign cells. The ANA test detects these autoantibodies in the blood. It thus serves as a crucial tool in diagnosing and managing autoimmune disorders such as GBS, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). The Antinuclear Antibody Test Market is Segmented by Technique (Immunofluorescence Assay, ELISA, and Multiplex Assay), Products and Services (Reagents and Assay Kits, Systems, and Services), Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Other Applications), Distribution Channel (Hospitals, Clinical Laboratories, and Other Distribution Channels), and Geography(North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions, globally. The report offers the value (USD million) for the above segments.

By Technique
ELISA
Immunofluorescence Assay
Multiplex Assay
By Products and Services
Reagents and Assay Kits
Systems
Services
By Application
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Other Applications
By Distribution Channel
Hospitals
Clinical Laboratories
Other Distribution Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Antinuclear Antibody Test Market Size Summary

The antinuclear antibody test market is poised for significant growth, driven by the increasing prevalence of autoimmune diseases and the rising demand for effective diagnostic assays. The market is expected to expand steadily over the forecast period, supported by factors such as government initiatives, favorable medical insurance policies, and the introduction of new products. The market's growth trajectory was influenced by the COVID-19 pandemic, which highlighted the importance of autoantibody diagnostics in infected patients. Despite the subsiding number of COVID-19 cases, the potential for new variants continues to sustain the demand for antinuclear antibody tests. The market is characterized by the dominance of immunofluorescence assays, which are preferred for their sensitivity and rapid results, as well as their ability to identify various autoantibody patterns associated with different diseases.

North America is anticipated to lead the market, with the United States playing a pivotal role due to its high burden of autoimmune diseases and an aging population. The region's demand for early diagnosis and effective treatment is further bolstered by the launch of innovative diagnostic products. The market is moderately competitive, with major players like Grifols SA, Abbott Laboratories, and PerkinElmer Inc. actively engaging in product development and strategic partnerships to enhance their market positions. The ongoing research and development activities, along with investments in new diagnostic platforms, are expected to drive the market forward, despite challenges such as concerns over test reliability and limited awareness in developing economies.

Explore More

Antinuclear Antibody Test Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Government Initiatives with Growing Incidences of Autoimmune Diseases

      2. 1.2.2 Favorable Medical Insurance and Reimbuirsement Policies

    3. 1.3 Market Restraints

      1. 1.3.1 Increasing Concerns with Over Reliability of ANA Tests

      2. 1.3.2 Lack of Awareness of Disease and Effective Treatment in the Developing Economies

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 2.1 By Technique

      1. 2.1.1 ELISA

      2. 2.1.2 Immunofluorescence Assay

      3. 2.1.3 Multiplex Assay

    2. 2.2 By Products and Services

      1. 2.2.1 Reagents and Assay Kits

      2. 2.2.2 Systems

      3. 2.2.3 Services

    3. 2.3 By Application

      1. 2.3.1 Rheumatoid Arthritis

      2. 2.3.2 Systemic Lupus Erythematosus

      3. 2.3.3 Other Applications

    4. 2.4 By Distribution Channel

      1. 2.4.1 Hospitals

      2. 2.4.2 Clinical Laboratories

      3. 2.4.3 Other Distribution Channels

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle-East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Antinuclear Antibody Test Market Size FAQs

The Antinuclear Antibody Test Market is projected to register a CAGR of 12.5% during the forecast period (2024-2029)

Abbott Laboratories (Alere Inc), Antibodies Incorporated , Grifols SA, PerkinElmer Inc and Abcam plc (BioVision Inc) are the major companies operating in the Antinuclear Antibody Test Market.

Antinuclear Antibody Test Report Snapshots

Antinuclear Antibody Test Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)